SLx-2119-KD-025-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemESLx-2119Cat. No.: HY-15307CAS No.: 911417-87-3Synonyms: KD-025分式: CHNO分量: 452.51作靶點(diǎn): ROCK作通路: Cell Cycle/DNA Damage; Stem Cell/Wnt; TGF-beta/Smad儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMS

2、O : 29 mg/mL (64.09 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 2.2099 mL 11.0495 mL 22.0990 mL5 mM 0.4420 mL 2.2099 mL 4.4198 mL10 mM 0.2210 mL 1.1049 mL 2.2099 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存式和期限。體內(nèi)實(shí)驗(yàn) SLX-2119 is given in drinking water4.

3、 Slx-2119 is prepared in vehicle (0.4% methylcellulose)3.BIOLOGICAL ACTIVITY物活性 SLx-2119 (KD-025)是選擇性的 ROCK2 抑制劑，IC50 值為 105 nM。IC50 & Target ROCK2 ROCK11/3 Master of Small Molecules 您邊的抑制劑師www.MedChemE105 nM (IC50) 24 M (IC50)體外研究 SLx-2119 (40 M) induces significant down-regulations of Tsp-1 and CT

4、GF mRNA levels in PASMC. Themicroarray hybridized with aRNA from HMVEC treated with SLx-2119, shows a 5-times higher backgroundthan the other arrays 1.體內(nèi)研究 SLx-2119 (KD-025; 100, 200 or 300 mg/kg, i.p.) dose-dependently reduces infarct volume after transientmiddle cerebral artery occlusion. SLx-2119

5、 is at least as efficacious in aged, diabetic or female mice, as innormal adult males 2.PROTOCOLCell Assay 1 Western blots are used to determine whether HMVEC, NHDF and PASMC express ROCK1 and ROCK2.The cells are incubated for 24 hours in 3 mL culture media containing SLx-2119. All cells are collect

6、ed atpassage 3 and lysed on ice in 25 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% tritonX-100, 10% glycerol, 10 mMNaF and a protease inhibitor cocktail. Protein concentration is determined using a BCA protein assayreagent. Cell lysates (35 g) are separated on 7.5% or 12.5% SDSpolyacrylamide gels andtransf

7、erred to PVDF membrane filters. Membranes are blocked in 5% non-fat milk in TBS containing 0.1%Tween 20. Blots are probed with antibodies to ROCK1, ROCK2 or actin and washed well before incubationwith HRP-conjugated secondary antibodies and visualization with an enhanced chemiluminescence (ECL)kit.M

8、CE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Young adult (C57BL/6, 2-3 months old, male 22-30 g, female 16-23 g), aged (C57BL/6, 12 months old, 33-Administration 2 52 g) are used in all experiments. Vehicle (0.4% methylcellulose) or SLx-2119 (1

9、00, 200 or 300 mg/kg) isadministered every 12 h via orogastric gavage. The dosing paradigm is chosen based on thepharmacokinetic profile after oral administration in mice. Atorvastatin (4 mg/mL) is dissolved in phosphate-buffered saline (pH 7.4) containing 45% 3-hydroxypropyl-B-cyclodextrin and 10%

10、ethanol, and administeredat a dose of 20 mg/kg per day as a single daily intraperitoneal injection for 2 weeks.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) J Autoimmun. 2018 May;89:125-138. Neurobiol Dis. 2019 Apr;124:520-530. Sci Rep. 20

11、18 Feb 6;8(1):2477. Adipocyte. 2019 Dec;8(1):114-124. PLoS One. 2017 May 16;12(5):e0177332.See more customer validations on HYPERLINK / www.MedChemEREFERENCES2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemE1. Boerma, M., et al. Comparative gene expression profiling in three primary human cell lines

12、 after treatment with a novel inhibitor of Rhokinase or atorvastatin. Blood Coagul Fibrinolysis, 2008. 19(7): p. 709-18.2. Lee, J.H., et al. Selective ROCK2 Inhibition In Focal Cerebral Ischemia. Ann Clin Transl Neurol, 2014. 1(1): p. 2-14.3. Yang W, et al. Critical role of ROCK2 activity in facilitating mucosal CD4+ T cell activation in inflammatory bowel disease. J Autoimmun.2018 May;89:125-138.4. Chen W, et al. Screening RhoA/ROCK inhibitors for the ability to prevent chronic rejection of mouse cardiac allografts.Transpl Immunol.2018 Jun 6. pii: S0966-3274(18)30029-7.McePdfHe